SLC5A2 and type 2 diabetes mellitus: In this comparative effectiveness study, we found that second line treatment with SGLT-2 inhibitors for people with type 2 diabetes mellitus was more effective than sulfonylureas or DPP-4 inhibitors in reducing mean HbA1c levels, BMI, and systolic blood pressure after the risk of confounding was reduced using an instrumental variable analysis.